Brian Estabrook
Medical · Corning, CANPI 1407842933
Payments from drug & device makers
Across 174 payments — averaging $24.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Abbott$847
- Novartis$372
- Amgen$291
- Merck$261
- Esperion Therapeutics, Inc.$213
- plus $1K from 15 others
What the payments were for
- Food & beverage$4,239100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 54 | $1,095 |
| Abbott | 12 | $847 |
| Novartis | 19 | $372 |
| Amgen | 14 | $291 |
| Merck | 10 | $261 |
| Esperion Therapeutics, Inc. | 12 | $213 |
| Sanofi-aventis U.S. LLC | 10 | $213 |
| Boehringer Ingelheim | 11 | $197 |
| AstraZeneca | 11 | $172 |
| Lilly USA, LLC | 2 | $118 |
| Idorsia Pharmaceuticals US Inc | 1 | $109 |
| AbbVie | 4 | $70 |
| Edwards Lifesciences | 1 | $64 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $60 |
| Actelion Pharmaceuticals US, Inc. | 2 | $38 |
| Lexicon Pharmaceuticals, Inc. | 2 | $35 |
| Chiesi USA, Inc. | 1 | $26 |
| Amarin Pharma, Inc. | 2 | $26 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Pfizer | 1 | $14 |
| Heartflow, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,253 in reported general payments places this provider in the 85th percentile of 2,087 medical providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 33 | $40,579 |
| XareltoRivaroxaban | 32 | $34,357 |
| EntrestoSacubitril/Valsartan | 23 | $32,251 |
| Repatha SureclickEvolocumab | 12 | $9,660 |
| Ezetimibe | 45 | $2,231 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 69 | $1,652 |
| Atorvastatin Calcium | 142 | $1,249 |
| Metoprolol Succinate | 83 | $1,121 |
| Gabapentin | 24 | $767 |
| Lisinopril | 93 | $725 |
| Rosuvastatin Calcium | 36 | $725 |
| Levothyroxine Sodium | 48 | $719 |
| Amlodipine Besylate | 83 | $706 |
| Flecainide Acetate | 20 | $624 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 25 | $587 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14 | $40,57933 claims |
| Johnson & JohnsonXarelto | $1,095 | $34,35732 claims |
| NovartisEntresto | $372 | $32,25123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,087 medical providers in California.
Other medical in Corning
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- David DoriguzziLancaster$514K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
- Deirdre MoxleyFullerton$149K
- Tri leGardena$127K
- Linda RankLadera Ranch$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.